Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer

Abstract

Our findings suggest that the level of MDSCs in the peripheral blood but not in tumor tissues predicts recurrence after surgery.

Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis

“…Here we report that elevated LDN in the circulation of advanced lung cancer patients is associated with poor prognosis in a very similar manner to NLR, a value introduced by many studies as a prognostic factor for survival in many tumor types, including to some extent in NSCLC . Recently, Yamauchi et al described no increase in the presence of LDN (namely PMN‐MDSC in that study) in the peripheral blood of early stage (stage I‐III) NSCLC patients . In accordance with this, we find the proportion of LDN in the Peripheral blood mononuclear cells (PBMCs) fraction to be elevated only at later stages, with a clear trend for an increase at stage IIIb and significant increased levels in stage IV patients.…”

“…16 Recently, Yamauchi et al described no increase in the presence of LDN (namely PMN-MDSC in that study) in the peripheral blood of early stage (stage I-III) NSCLC patients. 44 In accordance with this, we find the proportion of LDN in the Peripheral blood mononuclear cells (PBMCs) fraction to be elevated only at later stages, with a clear trend for an increase at stage IIIb and significant increased levels in stage IV patients. It seems therefore that LDN may not be used as a diagnostic tool but could rather provide a prognostic tool, or a potential guidance for therapy.…”

Neutrophil Diversity in Health and Disease

“…Advanced cancer patients presented high frequencies of circulating CCR5 + cells with high expression of ARG1 and PD-L1, two important mediators of T cell suppression by neutrophils, suggesting that CCR5 + cells may have a stronger immunosuppressive phenotype than CCR5cells [112]. The same group also described a similar phenotype of CCR5 + circulating neutrophils in NSCLC [113]. In another study of colorectal cancer patients receiving any form of cancer therapy, the expression of CD38 was increased in circulating neutrophils relative to untreated patients and healthy donors [114].…”

Myeloid-derived suppressor cells—new and exciting players in lung cancer

“…However, there are still no uniform standards for surface molecular markers of human MDSCs, and many other markers are being reported gradually. From the perspective of LC, according to multicolor immunofluorescence staining evaluated by fluorescenceactivated cell sorting (FACS), the following phenotypes of MDSCs have been reported (shown in Table 1): CD11b + CD14 − CD15 + CD33 + [14], CD11b + CD14 + S100A9 + [15], CD16 low CD11b + CD14 − HLA-DR − CD15 + CD33 + [16], CD14 + HLA-DR −/low [17,18], B7-H3 + CD14 + HLA-DR −/low [19], CD11b + CD14 − HLA-DR − CD33 + CD15 + ILT3 high [20], Lin − CD14 − CD11b + CD39 + CD73 + [21], Lin − CD14 + CD11b + C D39 + CD73 + [21], Lin − CD14 + CD15 + H LA-DR − [22], Lin − C D14 + CD15 − HLA-DR − [22], Lin − CD14 − HLA-DR − [22], Lin-CD33 + CD14 + CD15 − HLA-DR − [25], CD33 + CD11b + CD14 − [27], CD33 + CD11b + CD14 + HLA-DR −/low [27], and CCR 5 + HLA-DR −/low CD11b + CD14 + CD15 − [28].…”

“…Most studies focus only on the proportion of MDSCs in the peripheral blood of patients with LC. Yamauchi et al also focused on changes in MDSCs in the tumor tissues of patients with resectable NSCLC [28]. A significant increase in the frequency of circulating M-MDSCs was observed in the NSCLC patients compared with healthy donors (HDs).…”